Oramed Story

<div class='circular--portrait' style='background:#006400;color: #F5FFFA;font-size:4em;'>OP</div>
ORMP -- USA Stock  

USD 7.51  1.29  14.66%

In spite of very unsteady technical and fundamental indicators, Oramed Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in February 2021. Will insiders continue to hold, or should we expect a sell-off?
Published over a month ago
View all stories for Oramed Pharma | View All Stories
Does Oramed Pharmaceuticals (NASDAQ:ORMP) have healthy technical and fundamental indicators based on the recent roll up?
Oramed Pharmaceuticals is UNDERVALUED at 7.09 per share with modest projections ahead. Oramed Pharmaceuticals is relatively risky given 1 month investment horizon. Oramed Pharmaceuticals maintains Sharpe Ratio (i.e. Efficiency) of 0.22, which implies the firm had 0.22% of return per unit of risk over the last month. Our standpoint towards forecasting the risk of a stock is to use both market data as well as company specific technical data. We were able to analyze and collect data for twenty-eight different technical indicators, which can help you to evaluate if expected returns of 1.54% are justified by taking the suggested risk. Use Oramed Pharmaceuticals Coefficient Of Variation of 643.41, semi deviation of 3.66, and Risk Adjusted Performance of 0.1593 to evaluate company specific risk that cannot be diversified away.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Oramed Pharma income statement, its balance sheet, and the statement of cash flows. Potential Oramed Pharma investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Oramed Pharma investors may use each financial statement separately, they are all related. The changes in Oramed Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Oramed Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of Oramed Pharma fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Oramed Pharma performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Oramed Pharma shares is the value that is considered the true value of the share. If the intrinsic value Oramed is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Oramed Pharma.
Please read more on our fundamental analysis page.

Are Oramed Pharma Earnings Expected to grow?

The future earnings power of Oramed Pharma involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Oramed Pharma factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Oramed Pharma stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Oramed expected earnings.

How Oramed utilizes its cash?

To perform a cash flow analysis of Oramed Pharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Oramed Pharma is receiving and how much cash it distributes out in a given period. The Oramed Pharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Breaking it down

The company reported the previous year's revenue of 2.71 M. Net Loss for the year was (14.54 M) with profit before overhead, payroll, taxes, and interest of 2.71 M.

Another 3 percent roll up for Oramed Pharmaceuticals

Oramed Pharmaceuticals recent information ratio upswings over 0.12. As of the 22nd of January, Oramed Pharmaceuticals holds the Risk Adjusted Performance of 0.1593, coefficient of variation of 643.41, and Semi Deviation of 3.66. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Oramed Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Oramed Pharmaceuticals, which can be compared to its competitors. Please check Oramed Pharmaceuticals standard deviation, as well as the relationship between the maximum drawdown and expected short fall to decide if Oramed Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 5.53 per share. Given that Oramed Pharmaceuticals has jensen alpha of 1.12, we recommend you to check out Oramed Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Our Bottom Line On Oramed Pharmaceuticals

Although some other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Oramed Pharmaceuticals may offer a potential longer-term growth to insiders. To conclude, as of the 22nd of January 2021, we believe that at this point, Oramed Pharmaceuticals is undervalued with very small probability of bankruptcy within the next 2 years. However, our ongoing buy-or-sell advice on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Oramed Pharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com